Healthcare Sector Companies to See: Ariad Pharmaceuticals (ARIA), Raptor Pharmaceutical (RPTP)


Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

Stock’s Trading Stats:

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) surged 2.03% yesterday and closed at $6.52. The company’s market capitalization is at $1.25Billion with an average trading volume of 4.38 Million. The total number of Outstanding Shares Held by the company are 190.18Million.

Recent Press Release:

Ariad Pharmaceuticals, Inc. (ARI) on March 29, 2016 declared that it is reducing about 25 percent of its headquarter positions. The reduction includes about 90 positions in the U.S. and Europe. No customer-facing positions within ARIAD’s commercial or medical affairs organizations are included in this action.

This reduction in workforce is one of five key areas of ARIAD’s ongoing planned review. In addition to the decision declared recently, the review also includes an evaluation of commercial maximization programs, geographical presence, R&D portfolio, and business development opportunities to support the overall planned direction. ARIAD plans to provide further details on the progress of the planned review, which is aimed at increasing patient and shareholder value, in the second quarter of 2016.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP)

Stock’s Trading Stats:

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) closed at $4.67 yesterday by showing a increase of 1.97%. The total number of outstanding shares held by the company are 85.24 Million with the total market capitalization of $404.27 Million. The number of shares traded on the last trading session are 1.10 Million.

Recent Press Release:

Raptor Pharmaceutical Corp. (RPTP) on March 21, 2016 declared that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI® (cysteamine bitartrate) delayed-release capsules for the treatment of nephropathic cystinosis (NC), with Priority Review status. Priority Review provides for a shortened review process of 180 days contrast to a standard 300 days. Raptor estimates, based on information offered by physicians, that there are about 100 individuals affected by nephropathic cystinosis in Canada. PROCYSBI, a cystine depleting agent, is approved in the U.S. for the treatment of NC in adults and children ages two years and older and in all patients with NC in Europe.

PROCYSBI is a cystine depleting agent that is approved in the U.S. for the treatment of nephropathic cystinosis in adults and children ages two years and older. It is contraindicated in patients with a hypersensitivity to penicillamine. The most commonly stated side effects are vomiting, abdominal pain/discomfort, headaches, nausea, diarrhea, anorexia/reduced appetite, breath odor, fatigue, dizziness, skin odor and rash. For additional information on PROCYSBI, counting full prescribing information, please visit